← Eichor
Condition: Relapsed Or Refractory Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Or Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT07545603NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L
Phase 2 · 23 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03936153Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 · 31 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05476770A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/Phase 3 · 12 location(s) · Merck Sharp & Dohme LLC · NCT07570173Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05366179JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NA · 1 location(s) · Affiliated Hospital of Guangdong Medical University · NCT06940960Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Phase 1 · 1 location(s) · Sichuan University · NCT06348797A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Phase 2 · 1 location(s) · Ascentage Pharma Group Inc. · NCT04496349First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03986034A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/Phase 2 · 12 location(s) · Ascentage Pharma Group Inc. · NCT04501120CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT05143996Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Phase 1 · 7 location(s) · Marker Therapeutics, Inc. · NCT05798897A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Phase 1/Phase 2 · 6 location(s) · Recursion Pharmaceuticals Inc. · NCT06678659CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06693973A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Phase 2 · 1 location(s) · Shanghai Ming Ju Biotechnology Co., Ltd. · NCT06479356Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06034561Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Phase 1 · 2 location(s) · Nanjing Children's Hospital · NCT06751134A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Ly
Phase 1 · 1 location(s) · Ruijin Hospital · NCT07072169
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.